Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Genomics of gynaecological carcinosarcomas and future treatment options.

Barker HE, Scott CL.

Semin Cancer Biol. 2019 Oct 14. pii: S1044-579X(19)30295-0. doi: 10.1016/j.semcancer.2019.10.006. [Epub ahead of print] Review.

PMID:
31622660
2.

Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

van Rijswijk RE, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanaboni F, Mangili G, Vergote I, Guastalla JP, ten Bokkel Huinink WW, Lacave AJ, Bonnefoi H, Tumulo S, Rietbroek R, Teodorovic I, Coens C, Pecorelli S.

Eur J Cancer. 2003 Mar;39(4):481-7.

PMID:
12751379
3.

In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.

McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, Mackenzie R, McAlpine JN, Huntsman DG, Clarke BA, Gilks CB, Lee CH.

J Pathol Clin Res. 2015 Apr 9;1(3):173-85. doi: 10.1002/cjp2.18. eCollection 2015 Jul.

4.

Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.

Trento M, Munari G, Carraro V, Lanza C, Salmaso R, Pizzi S, Santoro L, Chiarelli S, Dal Santo L, Nardelli GB, Saccardi C, Nicoletto O, Baldoni A, Rugge M, Fassan M.

Int J Gynecol Pathol. 2019 Nov 1. doi: 10.1097/PGP.0000000000000645. [Epub ahead of print]

PMID:
31688243
5.

Oncogene alterations in endometrial carcinosarcomas.

Biscuola M, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J.

Hum Pathol. 2013 May;44(5):852-9. doi: 10.1016/j.humpath.2012.07.027. Epub 2012 Nov 28.

PMID:
23199529
6.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

7.

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.

Cicin İ, Özatlı T, Türkmen E, Özturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M, Arpaci E, Sevinç A.

Balkan Med J. 2016 Sep;33(5):517-524. Epub 2016 Sep 1.

8.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. Review.

PMID:
25341582
9.

Extravascular migratory metastasis in gynaecological carcinosarcoma.

Dyke JM, Crook ML, Platten M, Stewart CJ.

Histopathology. 2014 Sep;65(3):363-70. doi: 10.1111/his.12395. Epub 2014 Apr 16.

PMID:
24734932
10.

Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.

Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y.

Cancer Res. 1997 Dec 1;57(23):5379-85.

11.

PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.

Pinto A, Mackrides N, Nadji M.

Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):393-397. doi: 10.1097/PAI.0000000000000457.

PMID:
27801734
12.

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

McCluggage WG.

J Clin Pathol. 2002 May;55(5):321-5. Review.

13.

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.

Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR.

Gynecol Oncol. 2011 Apr;121(1):212-7. doi: 10.1016/j.ygyno.2010.11.039. Epub 2010 Dec 17.

PMID:
21168197
14.

Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multiinstitutional Study.

Abdulfatah E, Lordello L, Khurram M, Van de Vijver K, Alosh B, Bandyopadhyay S, Oliva E, Ali-Fehmi R.

Int J Gynecol Pathol. 2018 Apr 3. doi: 10.1097/PGP.0000000000000497. [Epub ahead of print]

PMID:
29620586
15.

Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study.

Abdulfatah E, Lordello L, Khurram M, Van de Vijver K, Alosh B, Bandyopadhyay S, Oliva E, Ali-Fehmi R.

Int J Gynecol Pathol. 2019 May;38(3):205-215. doi: 10.1097/PGP.0000000000000497.

PMID:
30958427
16.

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, Scarselli G, Taddei GL.

Gynecol Oncol. 2005 Jan;96(1):159-67.

PMID:
15589595
17.

Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.

Zhang C, Hu W, Jia N, Li Q, Hua K, Tao X, Wang L, Feng W.

Int J Gynecol Cancer. 2015 May;25(4):629-36. doi: 10.1097/IGC.0000000000000350.

PMID:
25633654
18.

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.

de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H.

Mod Pathol. 2011 Oct;24(10):1368-79. doi: 10.1038/modpathol.2011.88. Epub 2011 May 13.

19.

Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.

Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E.

Int J Cancer. 2002 Sep 10;101(2):190-5.

20.

Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas.

Chui MH, Have C, Hoang LN, Shaw P, Lee CH, Clarke BA.

J Pathol Clin Res. 2018 Jan 24;4(1):69-78. doi: 10.1002/cjp2.89. eCollection 2018 Jan.

Supplemental Content

Support Center